0 0.00

Shopping Cart ( 0 )

Your Have 0 Item In Your Cart

close

No products in the cart.

Nuffood Spectrum Publishes : Indo-German nutraceutical product shows promising sign for COVID-19 treatment – The product is considered effective against emerging SARS-C0V-2 variants

  • Home
  • Blog
  • Nuffood Spectrum Publishes : Indo-German nutraceutical product shows promising sign for COVID-19 treatment – The product is considered effective against emerging SARS-C0V-2 variants

Indo-German nutraceutical product shows promising sign for COVID-19 treatment

Link: https://nuffoodsspectrum.in/news/25/8472/indo-german-nutraceutical-product-shows-promising-sign-for-covid-19-treatment.html

25 June 2021 | News

The product is considered effective against emerging SARS-C0V-2 variants

Vedicinals, a German-Indian biotech company based in Pune, India has recently announced the results of a WHO registered randomized clinical trial using its Indian regulatory authority approved nutraceutical compound called Vedicinals9.

The clinical trial which involved 124 patients with almost half using the nutraceutical product alongside standard approved COVID-19 treatment protocols showed better clinical outcomes including faster viral clearance, accelerated repair of lung damage, prevention of severe COVID-19 disease progression, improvements of various key biomarkers such as  IL-6 and CRP, faster resolution of clinical symptoms such as fever, cough, fatigue etc and also organ protection.

Vedicinals9 consists of 9 bioactive molecules including Baicalin, Quercetin, Luteolin, Rutin, Hesperedin Curcumin, Epigallocatechin Gallate, Piperine, Glycyrrhizin. All these 9 bioactive molecules were selected based on silico studies, meta-analysis of past published studies, various studies on their drug target pathways and also their ability to be able to correct or stop various human host cellular pathways disruptions caused by the SARS-CoV-2 coronavirus.

Vedicinals9 has already been used in a variety of hospital settings throughout India with positive results and is now available throughout the country at leading hospitals, clinics, pharmacies and also through Vedicinals own online shop.

The product is being sold at a net price of about $135 for the Indian market for a set of 14 doses. This is merely an introductory price for the next few months to help as many locals access the product at an affordable price. The product is priced much higher in overseas markets.

The product is currently undergoing observational clinical studies in Columbia, Brazil, Iran and Pakistan. A larger randomized human clinical trial is being planned for the United States in the state of Oregon and also in UK.

The product is also undergoing regulatory approval as a nutraceutical supplement in Japan, Thailand, Australia, Indonesia and Singapore.

Prakash Salunte, Managing Director of Vedicinals Pvt Ltd said, “As of Today (21st June 2021) our product Vedicinals-9 is certified as a nutraceutical product in India by the FSSAI.”

Leave a Reply

Your email address will not be published. Required fields are marked *

Translate